User profiles for T.D. Swarthout
 | Todd SwarthoutAssistant Professor, Julius Center for Health Sciences and Primary Care, UMC Utrecht … Verified email at umcutrecht.nl Cited by 1772 |
[HTML][HTML] Multiple Origins and Regional Dispersal of Resistant dhps in African Plasmodium falciparum Malaria
…, W Mbacham, IV van den Broek, TD Swarthout… - PLoS …, 2009 - journals.plos.org
… As trial coordinator in Shabunda, Democratic Republic of the Congo, coordinated the trial
and participated in enrolling patients and collection of biological samples: T Swarthout. …
and participated in enrolling patients and collection of biological samples: T Swarthout. …
[HTML][HTML] Paracheck-Pf® accuracy and recently treated Plasmodium falciparum infections: is there a risk of over-diagnosis?
TD Swarthout, H Counihan, RKK Senga… - Malaria journal, 2007 - Springer
Background An assessment of the accuracy of Paracheck Pf ® , a malaria rapid diagnostic
test (RDT) detecting histidine rich protein 2 was undertaken amongst children aged 6–59 …
test (RDT) detecting histidine rich protein 2 was undertaken amongst children aged 6–59 …
[HTML][HTML] High residual carriage of vaccine-serotype Streptococcus pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi
There are concerns that pneumococcal conjugate vaccines (PCVs) in sub-Saharan Africa
sub-optimally interrupt Streptococcus pneumoniae vaccine-serotype (VT) carriage and …
sub-optimally interrupt Streptococcus pneumoniae vaccine-serotype (VT) carriage and …
[HTML][HTML] Waning of antibody levels induced by a 13-valent pneumococcal conjugate vaccine, using a 3+ 0 schedule, within the first year of life among children younger …
Background Pneumococcal conjugate vaccines (PCVs) induce serotype-specific IgG antibodies,
effectively reducing vaccine-serotype carriage and invasive pneumococcal disease (IPD…
effectively reducing vaccine-serotype carriage and invasive pneumococcal disease (IPD…
[HTML][HTML] Global landscape review of serotype-specific invasive pneumococcal disease surveillance among countries using PCV10/13: the pneumococcal serotype …
…, N Sinkovec Zorko, A Skoczyńska, TD Swarthout… - Microorganisms, 2021 - mdpi.com
Serotype-specific surveillance for invasive pneumococcal disease (IPD) is essential for
assessing the impact of 10- and 13-valent pneumococcal conjugate vaccines (PCV10/13). The …
assessing the impact of 10- and 13-valent pneumococcal conjugate vaccines (PCV10/13). The …
[HTML][HTML] The metabolic, virulence and antimicrobial resistance profiles of colonising Streptococcus pneumoniae shift after PCV13 introduction in urban Malawi
U Obolski, TD Swarthout, A Kalizang'oma… - Nature …, 2023 - nature.com
Streptococcus pneumoniae causes substantial mortality among children under 5-years-old
worldwide. Polysaccharide conjugate vaccines (PCVs) are highly effective at reducing …
worldwide. Polysaccharide conjugate vaccines (PCVs) are highly effective at reducing …
[HTML][HTML] Pneumococcal carriage in households in Karonga District, Malawi, before and after introduction of 13-valent pneumococcal conjugate vaccination
E Heinsbroek, T Tafatatha, A Phiri, TD Swarthout… - Vaccine, 2018 - Elsevier
Background Thirteen-valent pneumococcal conjugate vaccine (PCV13) was introduced in
Malawi in November 2011 and is offered to infants at 6, 10 and 14 weeks of age as part of …
Malawi in November 2011 and is offered to infants at 6, 10 and 14 weeks of age as part of …
Pan-GWAS of Streptococcus agalactiae highlights lineage-specific genes associated with virulence and niche adaptation
…, J Msefula, M Mallewa, Q Dube, TD Swarthout… - MBio, 2020 - Am Soc Microbiol
Streptococcus agalactiae (group B streptococcus; GBS) is a colonizer of the gastrointestinal
and urogenital tracts, and an opportunistic pathogen of infants and adults. The worldwide …
and urogenital tracts, and an opportunistic pathogen of infants and adults. The worldwide …
[HTML][HTML] Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal …
N Bar-Zeev, TD Swarthout, DB Everett… - The Lancet Global …, 2021 - thelancet.com
Background The population impact of pneumococcal conjugate vaccines (PCVs) depends
on direct and indirect protection. Following Malawi's introduction of the 13-valent PCV (PCV13…
on direct and indirect protection. Following Malawi's introduction of the 13-valent PCV (PCV13…
[HTML][HTML] Determinants of high residual post-PCV13 pneumococcal vaccine-type carriage in Blantyre, Malawi: a modelling study
… TD Swarthout … Carriage data used in this study is made available in Swarthout et al. [22],
where the … Swarthout TD, Fronterre C, Lourenço J, et al. High residual prevalence of vaccine-…
where the … Swarthout TD, Fronterre C, Lourenço J, et al. High residual prevalence of vaccine-…